1. Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
- Author
-
Ravandi, Farhad, Jorgensen, Jeffrey L, O'Brien, Susan M, Jabbour, Elias, Thomas, Deborah A, Borthakur, Gautam, Garris, Rebecca, Huang, Xuelin, Garcia-Manero, Guillermo, Burger, Jan A, Ferrajoli, Alessandra, Wierda, William, Kadia, Tapan, Jain, Nitin, Wang, Sa A, Konoplev, Sergei, Kebriaei, Partow, Champlin, Richard E, McCue, Deborah, Estrov, Zeev, Cortes, Jorge E, and Kantarjian, Hagop M
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Clinical Research ,Rare Diseases ,Hematology ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Cancer ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Antineoplastic Combined Chemotherapy Protocols ,Female ,Flow Cytometry ,Humans ,Leukocyte Count ,Male ,Middle Aged ,Neoplasm ,Residual ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Prospective Studies ,Remission Induction ,Treatment Outcome ,Young Adult ,acute leukaemia ,flow cytometry ,minimal residual disease ,Cardiorespiratory Medicine and Haematology ,Immunology ,Cardiovascular medicine and haematology - Abstract
The prognostic value of minimal residual disease (MRD) assessed by multi-parameter flow cytometry (MFC) was investigated among 340 adult patients with B-cell acute lymphoblastic leukaemia (B-ALL) treated between 2004 and 2014 using regimens including the hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) backbone. Among them, 323 (95%) achieved complete remission (CR) and were included in this study. Median age was 52 years (range, 15-84). Median white blood cell count (WBC) was 9·35 × 10(9) /l (range, 0·4-658·1 ×1 0(9) /l). MRD by MFC was initially assessed with a sensitivity of 0·01%, using a 15-marker, 4-colour panel and subsequently a 6-colour panel on bone marrow specimens obtained at CR achievement and at approximately 3 month intervals thereafter. MRD negative status at CR was associated with improved disease-free survival (DFS) and overall survival (OS) (P = 0·004 and P = 0·03, respectively). Similarly, achieving MRD negative status at approximately 3 and 6 months was associated with improved DFS (P = 0·004 and P
- Published
- 2016